Navigation Links
Sunesis Reports Financial Results for the First Quarter 2009
Date:5/6/2009

in in nonclinical studies, planned additional clinical testing and development efforts, the timing of clinical trial enrollment and the anticipated announcement of clinical results. Words such as "continued," "significant," "progress," "potential," " activity," established," "enhanced," "realize" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis' current expectations. Forward-looking statements involve risks and uncertainties. Sunesis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to Sunesis' need for additional funding, the risk that Sunesis' drug development activities could be halted significantly or delayed for various reasons, the risk that Sunesis' clinical trials for voreloxin may not demonstrate safety or efficacy or lead to regulatory approval, the risk that preliminary data and trends may not be predictive of future data or results, the risk that Sunesis' nonclinical studies and clinical trials may not satisfy the requirements of the FDA or other regulatory agencies, risks related to the conduct of Sunesis' clinical trials, including the pace of enrollment, risks related to the manufacturing of voreloxin and the risk that Sunesis' proprietary rights may not adequately protect voreloxin. These and other risk factors are discussed under "Risk Factors" and elsewhere in Sunesis' Annual Report on Form 10-K/A for the year ended December 31, 2008, its quarterly report on Form 10-Q for the quarter ended March 31, 2009 and other filings with the Securities and Exchange Commission. Sunesis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with regard thereto or any chang
'/>"/>
SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
2. Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350
3. Sunesis Pharmaceuticals SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology
4. Sunesis Pharmaceuticals to Present at Healthcare Investor Conferences in March
5. Sunesis Pharmaceuticals Presents Nonclinical Data on SNS-595 at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
7. Sunesis Pharmaceuticals to Present at the Collins Stewart Fourth Annual Growth Conference
8. Sunesis Pharmaceuticals Announces Up To $43.5 Million Financing
9. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
10. Haemacure Reports Third Quarter 2007 Results
11. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015 Sheltering Arms announced that it ... House. The Mother Hale Learning Center meets a tremendous ... Education. Sheltering Arms will begin operating the site immediately ... by the center. , Opened in 2006, the Mother ... to five years, many of whom come from high-need ...
(Date:5/4/2015)... Unlike some camps, the Nike Middle School Running Camps are focused ... educate first and train second, with a significant amount of time ... are building the knowledge base needed to have a long and ... Effort Based Training, Running Heroes, Running Vocabulary, and Why am I ... not a camp where kids come to run and train hard ...
(Date:5/4/2015)... In response to the proposed mammography ... (USPSTF), Strategic Radiology® (SR®) fully aligns itself with ... Gynecologists (ACOG), the American College Of Surgeons, Susan ... (ACS), American College of Radiology (ACR), and Society ... screening mammography for women beginning at age 40 ...
(Date:5/4/2015)... For partners who’d like to become ... Astroglide TTC™ (Trying to Conceive) . Unlike traditional ... levels, Astroglide TTC™ is specially formulated to provide a ... Centers for Disease Control, an average of one ... sustaining a pregnancy, and over 7.4 million women ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Fast on ... Gladen’s documentary Trace Amounts, and Allison Folmar, JD, join ... conference held internationally. , On Sunday, May 24, the ... from autism possible?" Are you interested in Ryan Hinds' ... There: winning our war against autism was written ...
Breaking Medicine News(10 mins):Health News:Sheltering Arms Acquires the Mother Hale Learning Center 2Health News:US Sports Camps and Select Nike Running Camps Offer Programs for Middle School Runners 2Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 2Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 3Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 4Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 5Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 2Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 3Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 2Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 3Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 4
... an attempt to tackle the global threat from bird ... as it is felt that// it may provide the ... to set up such a system has been published ... surveillance measures through co-ordination between such international labs can ...
... supplementation during pregnancy can reduce the incidence of ... study published by American Journal of Obstetrics and ... by elevated blood pressure and proteinuria (high levels ... feet, hands and legs is usually seen. If ...
... to spread awareness about AIDS/HIV, the Rotarians of Malda ... a health awareness program// ('One step for awareness about ... barbers. ,The local barbers, under the guidance ... AIDS/HIV awareness session was conducted at Rotary Bhawan. The ...
... A study carried in eight Ethiopian villages for two years ... to nip infection causing trachoma, which happens to be the// ... one Tanzanian village had seemed to show that a single ... the infection. A new study has suggested that the infection ...
... great grandfather at 79 and a war veteran, having braved ... met his end at the hands of a// nurse, who ... to give him a good night’s sleep. ,Hull Crown ... Heaton, aged 79 by giving him a sedative injection that ...
... widely prescribed by the physicians to those in the ... abnormal heart rhythm. They are less commonly given to ... the highest. In case of elders also those who ... prescribed warfarin when they are discharged. The study results ...
Cached Medicine News:Health News:Warfarin the Not So Popular Drug for Stroke 2
(Date:5/4/2015)... CARLSBAD, Calif. , May 4, 2015  Isis ... an exclusive license agreement with Bayer HealthCare (Bayer) to ... of thrombosis. Under the terms of the agreement, Isis ... near-term payments, including an immediate $100 million up-front payment ... program following a Phase 2 study in patients with ...
(Date:5/4/2015)... NEW YORK , May 4, 2015  FireflySci Inc., the newest member of the ... months after launch, they have turned the cuvette industry on its head by offering scientists amazing ... http://photos.prnewswire.com/prnh/20150501/213243LOGO Photo - http://photos.prnewswire.com/prnh/20150501/213244 ... ... ...
(Date:5/4/2015)... 2015 Intarcia Therapeutics, Inc. ... into the newly created role of Chief ... pharmaceutical executive with world-class experience – most recently ... service at industry leaders such as Pfizer and ... range of therapeutic areas, including: cardiovascular, metabolic, oncology, ...
Breaking Medicine Technology:Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 4Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 5New Cuvette Manufacturer Delivers Fast, Easy Solutions for Even the Hardest Cuvette Experiments 2New Cuvette Manufacturer Delivers Fast, Easy Solutions for Even the Hardest Cuvette Experiments 3Intarcia Names Top Commercial Expert Michael Williams As COO; Will Chair Commercial Committee And Lead ITCA 650 Launch In U.S. 2Intarcia Names Top Commercial Expert Michael Williams As COO; Will Chair Commercial Committee And Lead ITCA 650 Launch In U.S. 3Intarcia Names Top Commercial Expert Michael Williams As COO; Will Chair Commercial Committee And Lead ITCA 650 Launch In U.S. 4
Latex agglutination slide test for the qualitative and semi-quantitative in vitro determination of CRP in serum....
For the quantitative in vitro determination of Apolipoprotein A-1 in human serum....
For the quantitative determination of apolipoprotein B (apo B) in serum and plasma....
The GGT method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of g-glutamyl transferase activity in serum and plasma...
Medicine Products: